Correlation between vascular endothelial growth factor+936C/T polymorphism and colorectal cancer risk:a Meta analysis
ZHOU Chun-hua1 YUAN Song-quan2 LI Mei-zhen3▲
1.Department of Pulmonary/Gastrointestinal Diseases,Hunan Cancer Hospital(the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University)in Hunan Province,Changsha 410013,China;
2.Zhuzhou Foreign Language School in Hunan Province,Zhuzhou 412000,China;
3.Research Institute of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences,Central South University in Hunan Province,Changsha 410000,China
Abstract：ObjectiveTo investigate the association between the vascular endothelial growth factor(VEGF)gene+936C/T polymorphisms and colorectal cancer(CRC)risk.MethodsRelevant published case-control studies were searched in PubMed,Embase and Medline databases,and all documents were updated to October 2016.A comprehensive meta-analysis was then performed with Review Manager 4.2 and Stata 11.0 software in this work.ResultsFinally 10 studies including 2860 cases and 3080 controls were brought into our meta-analysis.The association between VEGF+936C/T polymorphisms and CRC risk were calculated with OR and their corresponding 95%CI,and stratified analysis was also conducted with respect to ethnicity.Combined analysis revealed that no significant association between VEGF+936C/T polymorphismandCRCriskwasidentifiedinallcomparisonmodelsincludingTallele vs.Callele[OR=1.04,95%CI(0.87,1.25), P=0.63],CT+TT vs.CC[OR=1.06,95%CI(0.86,1.30),P=0.61],TT vs.CC+CT[OR=1.10,95%CI(0.85,1.41),P=0.47],and TT vs. CC[OR=1.17,95%CI(0.91,1.52),P=0.22].Moreover,a similar result was obtained in the subgroup analysis that no significant association with CRC risk was found in all comparison models of VEGF+936C/T polymorphism in both Caucasian and Asian populations.ConclusionIt has been proved that VEGF+936C/T polymorphism might not be a risk factor for colorectal cancer,but further studies with larger sample sizes are required to make a better assessment of above association.
Wirasorn K，Suwanrungruag K，Wiangnon S，etal.Numbers of new cases and trends of cancer 1993-2012：srinagarind hospital based population，khon kaen，North-East Thailand[J]. Asian Pac J Cancer Prev，2014，15（19）：8423-8427.
[2]
Galizia G，Lieto E，Ferraraccio F，et al.Determination of molecular marker expression can predict clinical outcome in colon carcinomas[J].Clin Cancer Res，2004，10（10）：3490-3499.
[3]
Alvarez-Chaver P，Otero-Estevez O，Paez DLCM，et al. Proteomics for discovery of candidate colorectal cancer biomarkers[J].World J Gastroenterol，2014，20（14）：3804-3824.
[4]
Chekhonin VP，Shein SA，Korchagina AA，et al.VEGF in tumor progression and targeted therapy[J].Curr Cancer Drug Targets，2013，13（4）：423-443.
[5]
Kaio E，Tanaka S，Kitadai Y，et al.Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma[J].Oncology-Basel，2003，64 （1）：61-73.
[6]
Pare-Brunet L，Glubb D，Evans P，et al.Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway[J].Hum Mutat，2014，35（2）：227-235.
[7]
Almawi WY，Saldanha FL，Mahmood NA，et al.Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage[J].Hum Reprod，2013，28（10）：2628-2635.
[8]
Luo T，Chen L，He P，et al.Vascular endothelial growth factor（VEGF）gene polymorphisms and breast cancer risk in a Chinese population[J].Asian Pac J Cancer Prev，2013，14（4）：2433-2437.
[9]
Eng L，Azad AK，Habbous S，et al.Vascular endothelial growth factor pathway po lymorphisms as prognostic and pharmacogenetic factors in cancer：a systematic review and meta-analysis[J].Clin Cancer Res，2012，18（17）：4526-4537.
[10]
Bae SJ，Kim JW，Kang H，et al.Gender-specific association between polymorphism of vascular endothelial growth factor （VEGF 936 C>T）gene and colon cancer in Korea[J]. Anticancer Res，2008，28（2B）：1271-1276.
[11]
Chae YS，Kim JG，Sohn SK，et al.Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer[J].J Korean Med Sci，2008，23（3）：421-427.
[26]
Carmeliet P，Jain RK.Angiogenesis in cancer and other diseases[J].Nature，2000，407（6801）：249-257.
[12]
Hofmann G，Langsenlehner U，Renner W，et al.Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk[J].J Cancer Res Clin Oncol，2008，134（5）：591-595.
[13]
Dassoulas K，Gazouli M，Rizos S，et al.Common polymorphisms in the vascular endothelial growth factor geneand colorectalcancer development，prognosis，and survival[J].Mol Carcinog，2009，48（6）：563-569.
[14]
Ungerback J，Elander N，Dimberg J，et al.Analysis of VEGF polymorphisms,tumor expression of VEGF mRNA and colorectal cancer susceptibility in a Swedish population[J].Mol Med Rep，2009，2（3）：435-439.
[15]
Wu GY，Hasenberg T，Magdeburg R，et al.Association between EGF，TGF-beta1，VEGF gene polymorphism and colorectal cancer[J].World J Surg，2009，33（1）：124-129.
[16]
Wu X，Li D，Liu Z，et al.Vascular endothelial growth factor 1498C/T，936C/T polymorphisms associated with increased risk of colorectal adenoma：a Chinese case-control study[J]. Mol Biol Rep，2011，38（3）：1949-1955.
[17]
Antonacopoulou AG，Kottorou AE，Dimitrakopoulos FI，et al. VEGF polymorphisms may be associated with susceptibility to colorectal cancer：a case-control study[J].Cancer Biomark，2011，10（5）：213-217.
[18]
Jang MJ，Jeon YJ，Kim JW，et al.Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans[J].Mol Carcinog，2013，52 （Suppl 1）：E60-69.
[19]
Lau TP，Roslani AC，Lian LH，et al.Association between EGF and VEGF functional polymorphisms and sporadic colorectal cancer in the Malaysian population[J].Genet Mol Res，2014，13（3）：5555-5561.
[20]
Zhou LP，Luan H，Dong XH，et al.Vascular endothelial growth factor gene polymorphisms and colorectal cancer risk：a meta-analysis[J].Genet Mol Res，2011，10（4）：3674-3688.
[21]
Zhao Z，Ba C，Wang W，et al.Vascular endothelial growth factor（VEGF）gene polymorphisms and colorectal cancer：a meta-analysis of epidemiologic studies[J].Genet Test Mol Biomarkers，2012，16（12）：1390-1394.
[22]
Munafo MR，Clark TG，Flint J.Assessing publication bias in genetic association studies：evidence from a recent meta-analysis[J].Psychiatry Res，2004，129（1）：39-44.
[23]
Chootrakool H，Shi JQ，Yue R.Meta-analysis and sensitivity analysis for multi-arm trials with selection bias[J].Stat Med，2011，30（11）：1183-1198.
[24]
Sterne JA，Egger M，Smith GD.Systematic reviews in health care：Investigating and dealing with publication and other biases in meta-analysis[J].BMJ，2001，323（7304）：101-105.
[25]
YancopoulosGD，DavisS，Gale NW，etal.Vascularspecific growth factors and blood vessel formation[J].Nature，2000，407（6801）：242-248.
[27]
Keyhani E，Muhammadnejad A，Behjati F，et al.Angiogenesis markers in breast cancer-potentially useful tools for priority setting of anti-angiogenic agents[J].Asian Pac J Cancer Prev，2013，14（12）：7651-7656.
[28]
Kilic E，Schild SE，Thorns C，et al.Prognostic role of vascular endothelial growth factor and its receptor-1 in patients with esophageal cancer[J].Anticancer Res，2014，34（9）：5221-5226.
[29]
Bestas R，Kaplan MA，Isikdogan A.The correlation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma[J].Hepatogastroenterology，2014，61 （130）：267-271.
[30]
Zhang SJ，Hu Y，Qian HL，et al.Expression and significance of ER，PR，VEGF，CA15-3，CA125 and CEA in judging the prognosis of breast cancer[J].Asian Pac J Cancer Prev，2013，14（6）：3937-3940.
[31]
Hansen TF，Jakobsen A.Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer[J].Pharmacogenomics，2011，12（12）：1681-1693.
[32]
Zhou JY，He LW，Liu J，et al.Comprehensive assessment of associations between ERCC2 Lys751Gln/Asp312Asn polymorphisms and risk of non-Hodgkin lymphoma[J].Asian Pac J Cancer Prev，2014，15（21）：9347-9353.
京公网安备 11010502046607号